Atorvastatin

Manasa Life Sciences is a leading innovator in pharmaceutical reference standards. We supply high-quality Reference Standards of Atorvastatin, pharmacopeial and non-pharmacopeial Atorvastatin impurities, metabolites, stable isotope products, and nitrosamines (N-NO products). Atorvastatin impurities reference standards are useful in pharmaceutical research. They are useful in product development, ANDA and DMF filing, quality control (QC), method validation, and stability studies. It is also useful in the identification of unknown impurities and the assessment of genotoxic potential.

Atorvastatin-related products are thoroughly characterized. Atorvastatin products are supplied with detailed COA & analytical data meeting regulatory compliance. We can also provide EP/USP traceable standards based on your requirements. The supplied products are re-tested at regular intervals.

Approval:

Atorvastatin was patented in 1986, and approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2021, it was the most commonly prescribed medication in the United States, with more than 116 million prescriptions filled for over 28 million patients.

Medical uses:

The primary use of atorvastatin is for the treatment of dyslipidemia and the prevention of cardiovascular disease.

Combination:

1. Ezetimibe/atorvastatin 

Brand Name: (Liptruzet, Atozet)

Liptruzet was withdrawn from sale by its manufacturer in June 2015, but not for reasons of safety or effectiveness.

2. Amlodipine/atorvastatin 

Brand Name: Caduet

Caduet is a fixed-dose combination medication for the treatment of high cholesterol and high blood pressure. It contains a statin and a calcium channel blocker.